secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001628280-25-020257
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn presents AACR preclinical data for FHD-909 and CBP/EP300 degraders; Phase 1 ongoing
--------------------------------------------------------------------------------

- FHD-909 (SMARCA2 inhibitor) Phase 1 trial ongoing in SMARCA4-mutated solid tumors; NSCLC primary target.
- Preclinical combo data: FHD-909 synergistic with pembrolizumab and KRAS inhibitors, supporting clinical exploration.
- Selective CBP degrader synergistic with paclitaxel and abemaciclib in ER+ breast cancer models.
- Selective EP300 degrader shows preclinical activity in DLBCL and multiple myeloma; no thrombocytopenia.
- ARID1B degrader program update expected in 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025020257/0001628280-25-020257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025020257/fhtx-20250428.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-020257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer